TY - JOUR T1 - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant JF - medRxiv DO - 10.1101/2022.01.17.22269222 SP - 2022.01.17.22269222 AU - Alexandra B Hogan AU - Sean L Wu AU - Patrick Doohan AU - Oliver J Watson AU - Peter Winskill AU - Giovanni Charles AU - Gregory Barnsley AU - Eleanor M Riley AU - David S Khoury AU - Neil M Ferguson AU - Azra C Ghani Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/18/2022.01.17.22269222.abstract N2 - Vaccines have played a central role in mitigating severe disease and death from COVID-19 in the past 12 months. However, efficacy wanes over time and this loss of protection is being compounded by the emergence of the Omicron variant. By fitting an immunological model to population-level vaccine effectiveness data, we estimate that neutralizing antibody titres for Omicron are reduced by 3.9-fold (95% CrI 2.9–5.5) compared to the Delta variant. Under this model, we predict that 90 days after boosting with the Pfizer-BioNTech vaccine, efficacy against severe disease (admission to hospital) declines to 95.9% (95% CrI 95.4%–96.3%) against the Delta variant and 78.8% (95% CrI 75.0%–85.1%) against the Omicron variant. Integrating this immunological model within a model of SARS-CoV-2 transmission, we demonstrate that the size of the Omicron wave will depend on the degree of past exposure to infection across the population, with relatively small Omicron waves in countries that previously experienced a large Delta wave. We show that booster doses can have a major impact in mitigating the epidemic peak, although in many settings it remains possible that healthcare capacity could still be challenged. This is particularly the case in “zero-COVID” countries where there is little prior infection-induced immunity and therefore epidemic peaks will be higher. Where dose supply is limited, targeting boosters to the highest risk groups to ensure continued high protection in the face of waning immunity is of greater benefit than giving these doses as primary vaccination to younger age-groups. In many settings it is likely that health systems will be stretched, and it may therefore be necessary to maintain and/or reintroduce some level of NPIs to mitigate the worst impacts of the Omicron variant as it replaces the Delta variant.Competing Interest StatementACG is a non-renumerated member of a scientific advisory board for Moderna, has received consultancy funding from GSK for educational activities related to COVID-19 vaccination and is a member of the CEPI scientific advisory board. She has received grant funding from Gavi for COVID-19 related work. ABH, PW and ACG have previously received consultancy payments from WHO for COVID-19 related work. ABH was previously engaged by Pfizer Inc to advise on modelling RSV vaccination strategies for which she received no financial compensation. EMR is a non-remunerated member of the UK Vaccines Network, the UKRI COVID-19 taskforce and the British Society for Immunology Covid-19 taskforce.Funding StatementThis work was supported by a grant from WHO. ABH and PW are supported by Imperial College Research Fellowships. PD is supported by the Jameel Institute. OJW is supported by a Schmidt Science Fellowship in partnership with the Rhodes Trust. GC and ACG acknowledge support from The Wellcome Trust. ABH, PD, PW, GC, GB, SLW, NMF and ACG acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), funded by the UK Medical Research Council (MRC) and part of the EDCTP2 programme supported by the European Union; and from the Jameel Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modelling study and did not collect primary data. All model code is available on Github.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available online on the Github link provided in the manuscript. https://mrc-ide.github.io/safir https://github.com/mrc-ude/global_covid_vaccine_booster_paper. ER -